Nymox Pharmaceutical Corporation (NYMXF)

Nymox Pharmaceutical Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 4, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	5	9	55	30	110	192
Market Cap Growth	-17.20%	-82.82%	86.49%	-73.23%	-42.54%	24.63%
Enterprise Value	9	10	55	27	108	187
Last Close Price	0.05	0.10	0.59	0.32	1.30	2.48
PS Ratio	-	-	-	-	-	38367.59
PB Ratio	-0.80	-1.39	-17.34	-61.22	-217.85	89.44
P/TBV Ratio	-	-	-	-	-	89.44
EV/Sales Ratio	-	-	-	-	-	37312.99
Debt / Equity Ratio	-0.48	-0.48	-0.24	-0.36	-0.77	0.20
Net Debt / Equity Ratio	-0.47	-0.47	-0.21	2.55	0.87	-1.48
Net Debt / EBITDA Ratio	-0.75	-0.75	-0.08	0.19	0.04	0.27
Net Debt / FCF Ratio	-1.24	-1.24	-0.17	0.24	0.05	0.32
Asset Turnover	-	-	-	-	-	0.00
Inventory Turnover	-	-	-	-	-	0.14
Quick Ratio	0.01	0.01	0.02	0.67	0.47	1.85
Current Ratio	0.09	0.09	0.16	0.69	0.58	1.98
Return on Equity (ROE)	-	-	-	-	-1529.84%	-419.74%
Return on Assets (ROA)	-417.94%	-417.94%	-463.48%	-271.02%	-270.13%	-149.00%
Return on Capital Employed (ROCE)	63.20%	63.20%	263.20%	1380.10%	3645.50%	-492.90%
Earnings Yield	-82.86%	-47.51%	-16.07%	-22.29%	-11.37%	-6.12%
FCF Yield	-	-27.51%	-7.38%	-17.64%	-8.91%	-5.24%
Buyback Yield / Dilution	-3.05%	-2.16%	-2.58%	-9.04%	-11.04%	-7.23%

Updated Jan 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.